Gamida Cell wins additional EMA orphan drug designation for NiCord

Gamida Cell said today that the European Medicines Agency granted its NiCord cell graft an additional orphan drug designation as a treatment for hematopoietic stem cell transplantation, or bone marrow transplantation.

The treatment is a graft derived from umbilical cord blood which has been expanded and enriched with stem and progenitor cells, according to the company. The EMA previously granted orphan drug designation to NiCord for acute myeloid leukemia.

Get the full story at our sister site, Drug Delivery Business News.

The post Gamida Cell wins additional EMA orphan drug designation for NiCord appeared first on MassDevice.

from MassDevice http://ift.tt/2nHZjzl